In terms of invasive carcinoma, cases in which the in situ component was identified (n = 14), the luminal A immunophenotypical profile accounted for 50% of cases, the basal-like profile accounted for 35.8%, the luminal B accounted for 7.1%, and the HER2-like profile was evident in 7.1% of the samples. Here, ERBB2 is linked to invasive carcinoma.